Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q3 Revenues Climb 28.6 Percent, Losses Decline

NEW YORK, Oct. 27 (GenomeWeb News) - Luminex yesterday reported increased revenues and a narrowing loss for the third quarter of 2005 as a result of increased R&D investment.

 

Revenues for third quarter ended Sept. 30 totaled $10.8 million, a 28.7 percent increase over last year's revenues of $8.4 million during the same quarter. Of total revenues, $4.6 million came from sales of Luminex instruments, $3.4 million from consumables, $1.4 million from royalties, and $1.3 million from other sources such as training, extended service contract sales, and other special project revenue.

 

Research and development costs climbed to $1.5 million, up from $949,000 during the year-ago quarter.

 

Luminex's net loss declined 43 percent to $657,000, or $.02 per share, from $1.2 million, or $.04 per share, for last year's third quarter.

 

As of Sept. 30, Luminex had $21.5 million in cash and cash equivalents, and $10.9 million in short-term investments.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.